CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
SAN FRANCISCO, Aug. 6, 2026 /PRNewswire/ -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses...
Read moreDetails